Shanghai Rendu Biotechnology Co. Ltd. A (SHG:688193) — Market Cap & Net Worth
Market Cap & Net Worth: Shanghai Rendu Biotechnology Co. Ltd. A (688193)
Shanghai Rendu Biotechnology Co. Ltd. A (SHG:688193) has a market capitalization of $283.68 Million (CN¥1.94 Billion) as of September 24, 2026. Listed on the SHG stock exchange, this China-based company holds position #15237 globally and #4531 in its home market, demonstrating a 7.27% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Rendu Biotechnology Co. Ltd. A's stock price CN¥48.38 by its total outstanding shares 40069870 (40.07 Million). Also see Shanghai Rendu Biotechnology Co. Ltd. A assets under control for a full breakdown of the balance sheet.
Shanghai Rendu Biotechnology Co. Ltd. A Market Cap History: 2022 to 2026
Shanghai Rendu Biotechnology Co. Ltd. A's market capitalization history from 2022 to 2026. Data shows change from $270.36 Million to $283.68 Million (-6.02% CAGR). Also see 688193 cash flow metrics for how efficiently the company converts equity into cash flow.
Shanghai Rendu Biotechnology Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Rendu Biotechnology Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Shanghai Rendu Biotechnology Co. Ltd. A (688193) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.75x
Shanghai Rendu Biotechnology Co. Ltd. A's market cap is 1.75 times its annual revenue
Latest Price to Earnings (P/E) Ratio
28.12x
Shanghai Rendu Biotechnology Co. Ltd. A's market cap is 28.12 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $270.36 Million | $303.85 Million | $23.33 Million | 0.89x | 11.59x |
| 2023 | $261.86 Million | $164.41 Million | $8.26 Million | 1.59x | 31.71x |
| 2024 | $209.62 Million | $177.35 Million | -$7.81 Million | 1.18x | N/A |
| 2025 | $283.62 Million | $161.94 Million | $10.09 Million | 1.75x | 28.12x |
Competitor Companies of 688193 by Market Capitalization
Companies near Shanghai Rendu Biotechnology Co. Ltd. A in the global market cap rankings as of September 24, 2026. Review Shanghai Rendu Biotechnology Co. Ltd. A (688193) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Shanghai Rendu Biotechnology Co. Ltd. A by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #89 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #155 globally with a market cap of $156.17 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #456 globally with a market cap of $60.75 Billion USD ( CN¥415.14 Billion CNY).
- Natera Inc (NASDAQ:NTRA): Ranked #581 globally with a market cap of $47.01 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #89 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $658.52 |
| #155 | Danaher Corporation | NYSE:DHR | $156.17 Billion | $221.09 |
| #456 | WuXi AppTec Co Ltd | SHG:603259 | $60.75 Billion | CN¥167.85 |
| #581 | Natera Inc | NASDAQ:NTRA | $47.01 Billion | $390.90 |
Shanghai Rendu Biotechnology Co. Ltd. A Historical Marketcap From 2022 to 2026
Between 2022 and today, Shanghai Rendu Biotechnology Co. Ltd. A's market cap moved from $270.36 Million to $ 283.68 Million, with a yearly change of -6.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥283.68 Million | +0.02% |
| 2025 | CN¥283.62 Million | +35.30% |
| 2024 | CN¥209.62 Million | -19.95% |
| 2023 | CN¥261.86 Million | -3.14% |
| 2022 | CN¥270.36 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Shanghai Rendu Biotechnology Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $283.68 Million USD |
| MoneyControl | $283.68 Million USD |
| MarketWatch | $283.68 Million USD |
| marketcap.company | $283.68 Million USD |
| Reuters | $283.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai Rendu Biotechnology Co. Ltd. A
Shanghai Rendu Biotechnology Co., Ltd. engages in the research, development, production, and sales of RNA molecular diagnostic technology and products. It offers products in the areas of reproductive health, bloodborne infections, respiratory infections, enterovirus infections, cancer early detection, and other areas; and AutoSAT, SuperSAT, and ultrasonic homogenizer. The company was founded in 2… Read more